Baheal — which works with more than 12,000 hospitals in China — will sell Watson for Genomics to clinicians and researchers across the country.
Watson for Genomics analyzes patients' genomic, clinical and pharmacological data to identify personalized treatment options, such as genetic alterations, drugs and clinical trials.
"Despite the promise of precision medicine, data-driven challenges make it difficult for oncologists to bring genomic advances to their patients," said Gang Fu, chair of Baheal. "We believe Watson will help accelerate this growing field so that research advances can be accessed for patient benefit more quickly."
The Watson for Genomics agreement arrives less than three months after IBM and Baheal launched a strategic partnership to distribute Watson for Oncology in China. Baheal has since implemented Watson for Oncology at eight hospitals.
More articles on health IT:
Dr. Sean Tunis elected president of HTAi